Baird Capital portfolio company AiCure recently announced a Series C fundraising round totaling $24.5 million.

AiCure uses artificial intelligence to see, hear and understand how people respond to treatment across clinical trials and patient care. Clinically proven to accurately measure and modify patient behavior, AiCure's technologies keep patients engaged and optimized to treatment, as well as assess treatment effectiveness.

Read AiCure’s full news release here for more information.